[Clinical study on the using methods of cisplatin in lung cancer chemotherapy].
To compare the therapeutic effectiveness and toxicity between 1-day perfusion and 3-day perfusion of high-dose cisplatin combined chemotherapy for lung cancer. Sixty-four cases of pathologically proved lung cancer were randomized into groups A and B. Group A (32 cases) received cisplatin at d1, and group B (32 cases) received cisplatin at d1-3. Total dosages of cisplatin were same for both groups (100 mg/m²). Delayed vomiting in group B (40.63%) was significantly lower than that of group A (53.13%) (P<0.05); the early nephrotoxicity rate of group B(25.00%) was lower than that of group A (46.88%), but there was no statistically significant difference between two groups (P>0.05). The therapeutical response was 62.50% in group A, and 68.75% in group B. No significant difference of the chemotherapeutical response was observed between the two groups (P>0.05). In the combined chemotherapy of lung cancer, the division administration of high-dose cisplatin can not only guarantee the therapeutic response, but also abate the gastrotoxicity and the nephrotoxicity of cisplatin.